Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Nobori umirolimus-eluting stent versus Xience/Promus everolimus-eluting stent in patients in Japan

Next Previous
Trial Profile

Nobori umirolimus-eluting stent versus Xience/Promus everolimus-eluting stent in patients in Japan

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 24 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 30 Mar 2020 Primary endpoint has not been met. (Device-oriented composite endpoints (DOCE))
  • 30 Mar 2020 Results (N=2503) comparing Seven Year clinical outcomes between BP-BES (n=1343) and DP-EES (n=1160), presented at the 2020 Annual Scientific Session of the American College of Cardiology and World Congress of Cardiology
  • 25 Sep 2018 Results assessing Five-Year Clinical Outcomes of NOBORI Biolimus-Eluting Stent versus XIENCE Everolimus-Eluting Stent in Diabetic Patients (n=1069) presented at the 30th Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top